View printer-friendly version
« Back
November 05, 2002 4:24 p.m.
Teva Intends to Appeal Court Ruling on Fosamax®

Jerusalem, Israel, November 5, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Judge Farnan of the U.S. District Court in Wilmington, Delaware yesterday upheld a patent covering Fosamax® (alendronate sodium), a product of Merck & Co., Inc. The case had been brought by Merck against Teva and Zenith Goldline Pharmaceuticals, a unit of Ivax Pharmaceuticals, Inc. as a result of the patent challenge provisions of Paragraph IV of the Hatch Waxman Act.

Mr. Israel Makov, President and CEO of Teva said: "We have reviewed yesterday's decision, and are, of course, disappointed. Judge Farnan found that Teva infringed a single patent. We are still analyzing the 59-page decision, but we believe that there are substantial avenues for appeal, and will be requesting an expedited review from the Federal Circuit." Merck originally alleged that Teva had willfully infringed six patents, but prior to trial it dismissed its claims on five of the six patents, and dropped its allegation of willful infringement as to the sixth.

Because of a combination of Hatch Waxman stay periods and other anticipated regulatory constraints, had Teva won this decision it would not have anticipated launching this product prior to the latter part of 2003.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.